Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment

Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment

PreDiabetes

Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic

Ecdysterone

Placebo

The journal of clinical and applied research and education. Diabetes Care. American Diabetes Association. Standards of Medical Care in Diabetes-2019.

Ana Fletes

Effect of Phytoecdysterone Administration in Subjects With Prediabetes

Effect of Phytoecdysterone Administration on Cytotoxicity, Genotoxicity and Metabolic Control in Subjects With Prediabetes

The number of micronuclei will be evaluated at baseline and day 90 with Schmidt technique by giemsa/wright and the entered values reflect the number of micronuceli at day 90

The fasting glucose levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at day 90

Glycosylated hemoglobin will be evaluated at baseline and day 90 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at day 90

The body weight will be measured at baseline, day 30, day 60 and day 90 with a bioimpedance balance and the entered values reflect the body weight at 90 days

Body Mass Index will be calculated at baseline, day 30, day 60 and day 90 with the Quetelet index formula and the entered values reflect the body mass index at day 90

Waist circumference will be evaluated at baseline and at day 90 with a flexible tape

Total cholesterol levels will be evaluated at baseline and day 90 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at day 90

Triglycerides levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at day 90

c-HDL levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at day 90

c-LDL levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at day 90

Creatinine levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques

ALT levels will be evaluated at baseline and day 90 with enzymatic/colorimetric techniques

AST levels will be evaluated at baseline and day 90 enzymatic/colorimetric techniques

Blood pressure will be measured at baseline and day 90 with a digital sphygmomanometer and the entered values reflect the blood pressure at day 90

THE RESULTS GENERATED AND THE PERSONAL DATA OF THE PARTICIPANTS ARE ON THE CONSENT OF THE SUBJECT OF STUDY AND OF THE PRINCIPAL INVESTIGATOR. THEY ARE EXTRICTLY CONFIDENTIAL AND WILL ONLY BE USED BY HOSPITAL DOCTORS

Ana Lilia Fletes Rayas

Reseach Professor Associated

University of Guadalajara

cohort populations with diagnostic metabolic syndrome treatment base with ecdysterone for 90 days

Randomized double-blind clinical trial plus control group

ecdysterone/fetma

Effect of Phytoecdysterone Administration in Subjects With Prediabetes

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen